Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

Journal of Clinical Oncology

Volumn 25, Issue 10, 2007, Pages 1247-1254

  Ruzzo, Annamaria ^b   Graziano, Francesco ^a   Loupakis, Fotios ^b   Rulli, Eliana ^b   Canestrari, Emanuele ^b   Santini, Daniele ^b   Catalano, Vincenzo ^b   Ficarelli, Rita ^b   Maltese, Paolo ^b   Bisonni, Renato ^b   Masi, Gianluca ^b   Schiavon, Gaia ^b   Giordani, Paolo ^b   Giustini, Lucio ^b   Falcone, Alfredo ^b   Tonini, Giuseppe ^b   Silva, Rosarita ^b   Mattioli, Rodolfo ^b   Floriani, Irene ^b   Magnani, Mauro ^b  

^a UNIVERSITY OF URBINO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE; OXALIPLATIN; PEPTIDES AND PROTEINS; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; X RAY CROSS COMPLEMENTING PROTEIN GROUP 1; X RAY CROSS COMPLEMENTING PROTEIN GROUP 3; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; FOLFOX PROTOCOL; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD SAMPLING; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOLOGY; DIARRHEA; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; THROMBOCYTOPENIA; VOMITING; 5' UNTRANSLATED REGION; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY;

5' UNTRANSLATED REGIONS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; LEUCOVORIN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE;

EID: 34247105821     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.1844     Document Type: Article

References (65)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
2. Kelly H, Goldberg RM: Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 23:4553-4560, 2005
3. Falcone A, Masi G, Allegrini G, et al: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20: 4006-4014, 2002
4. Marsh S, McLeod HL: Cancer pharmacogenetics. Br J Cancer 90:8-11, 2004
5. Nagasubramanian R, Innocenti F, Ratain MJ: Pharmacogenetics in cancer treatment. Annu Rev Med 54:437-452, 2003
6. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol 22:529-536, 2004
7. Horie N, Aiba H, Oguro K, et al: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191-197, 1995
8. Kawakami K, Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of the thymidylate synthase gene. Cancer Res 63:6004-6007, 2003
9. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904, 2003
10. Kawakami K, Omura K, Kanehira E, et al: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249-3252, 1999
11. Morganti M, Ciantelli M, Giglioni B, et al: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41:2176-2183, 2005
12. Kawakami K, Watanabe G: The association of thymidylate synthase mRNA expression with its three gene polymorphisms in colorectal cancer. Proc Am Assoc Cancer Res 45:484, 2004 (abstr 2104)
13. Ulrich CM, Bigler J, Velicer CM, et al: Searching expressed sequence Tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9:1381-1385, 2000
14. Mandola MV, Stoehlmacher J, Zhang W, et al: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319-327, 2004
15. Sohn KJ, Croxford R, Yates Z, et al: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96:134-144, 2004
16. Etienne MC, Ilc K, Formento JL, et al: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: Relationships with 5-fluorouracil sensitivity. Br J Cancer 90:526-534, 2004
17. Kawakami K, Ruszkiewicz A, Bennett G, et al: The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 9:5860-5865, 2003
18. Paz MF, Avila S, Fraga MF, et al: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 62:4519-4524, 2002
19. Iacopetta B: Methyl-group metabolism and the response of colorectal cancer to 5-Fluorouracil. Crit Rev Oncogenesis 12:1-12, 2006
20. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320, 2005
21. Altaha R, Liang X, Yu JJ, et al: Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int J Mol Med 14:959-970, 2004
22. Weaver DA, Crawford EL, Warner KA, et al: ABCC5, ERCC2, XPA, and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 4:18, 2005
23. Furuta T, Ueda T, Aune G, et al: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899-4902, 2002
24. Xu ZY, Loignon M, Han FY, et al: Xrcc3 induces cisplatin resistance by stimulation of rad51-related recombinational repair, s-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 314:495-505, 2005
25. Raaphorst GP, Li LF, Yang DP: Evaluation of adaptive responses to cisplatin in normal and mutant cell lines with mutations in recombination repair pathways. Anticancer Res 26:1183-1187, 2006
26. Park DJ, Stoehlmacher J, Zhang W, et al: ERCC1 polymorphism is associated with differential ERCC1 mRNA levels. Proc Am Ass Cancer Res 43:321, 2002 (abstr. 1591)
27. Savas S, Kim DY, Ahmad MF, et al: Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 13:801-807, 2004
28. Lunn RM, Langlois RG, Hsieh LL, et al: XRCC1 polymorphisms: Effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59:2557-2561, 1999
29. Au WW, Salama SA, Sierra-Torres CH: Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111:1843-1850, 2003
30. Affatato AA, Wolfe KJ, Lopez MS, et al: Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. Environ Mol Mutagen 44:65-73, 2004
31. Lunn RM, Helzlsouer KJ, Parshad R, et al: XPD polymorphisms: Effects on DNA repair proficiency. Carcinogenesis 21:551-555, 2000
32. Spitz MR, Wu X, Wang Y, et al: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354-1357, 2001
33. Araujo FD, Pierce AJ, Stark JM, et al: Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 21:4176-4180, 2002
34. Seker H, Butkiewicz D, Bowman ED, et al: Functional significance of XPD polymorphic variants: Attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 61:7430-7434, 2001
35. Watson MA, Stewart RK, Smith GB, et al: Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19:275-280, 1998
36. Goto S, Iida T, Cho S, et al: Overexpression of glutathione S-transferase pi enhances the adduct formation of Cisplatin with glutathione in human cancer cells. Free Radic Res 31:549-558, 1999
37. Abdel-Rahman SZ, el-Zein RA, Anwar WA, et al: A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 107:229-233, 1996
38. Louvet C, de Gramont A, Tournigand C, et al: Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91:2033-2038, 2001
39. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
40. Lecomte T, Landi B, Beaune P, et al: Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12:3050-3056, 2006
41. Dupont WD, Plummer WD: Power and sample size calculations: A review and computer program. Controlled Clinical Trials 11:116-128, 1990
42. Massacesi C, Pistilli B, Valeri M, et al: A. Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. Am J Clin Oncol 25:140-148, 2002
43. Massacesi C, Norman A, Price T, et al: Clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 36:2044-2052, 2000
44. Cunningham D, Norman AR, Chong G, et al: Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 16:1305-1310, 2005
45. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenom J 1:65-70, 2001
46. Stoehlmacher J, Park DJ, Zhang W, et al: A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354, 2004
47. Jakobsen A, Nielsen JN, Gyldenkerne N, et al: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23:1365-1369, 2005
48. Dotor E, Cuatrecases M, Martinez-Iniesta M, et al: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24:1603-1611, 2006
49. Marcuello E, Altes A, del Rio E, et al: Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112:733-737, 2004
50. Pullmann R Jr, Abdelmohsen K, Lal A, et al: Differential stability of thymidylate synthase 3′UTR polymorphic variants regulated by AUF1. J Biol Chem 281:23456-23463, 2006
51. Uchida K, Hayashi K, Kawakami K, et al: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 10:433-139, 2004
52. Hoshino S, Yamashita Y, Maekawa T, et al: Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients. Cancer Chemother Pharmacol 56:648-652, 2005
53. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer - a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
54. Cohen V, Panet-Raymond V, Sabbaghian N, et al: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611-1615, 2003
55. Etienne MC, Formento JL, Chazal M, et al: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14:785-792, 2004
56. Marcuello E, Altes A, Menoyo A, et al: Methylenetetrahydrofolate reductase gene polymorphisms: Genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 5:1-6, 2005
57. Kweekel DM, Gelderblom H, Guchelaar HJ: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90-105, 2005
58. Park DJ, Zhang W, Stoehlmacher J, et al: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1:162-166, 2003
59. Park DJ, Stoehlmacher J, Zhang W, et al: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654-8658, 2001
60. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase PI, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936-942, 2002
61. Howie AF, Forrester LM, Glancey MJ, et al: Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis 11:451-458, 1990
62. Moscow JA, Fairchild CR, Madden MJ, et al: Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49:1422-1428, 1989
63. Ueda M, Hung YC, Terai Y, et al: Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell 16:241-251, 2003
64. Hayes JD, Wolf CR: Townsend DM, et al: The role of glutathione-S- transferase in anti-cancer drug resistance. Oncogene 22:7369-7377, 2003
65. Grothey A, McLeod HL, Green EM, et al: Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J Clin Oncol 23: 3509, 2005 (abstr 3509)